Canntab Therapeutics Ltd (CNSX:PILL) has now filed 11 patents related to pharmaceutical cannabis.
These filings, which include seven non-provisional United States patent applications and four patent co-operation treaty (PCT) patent applications, build on Canntab's growing intellectual property portfolio.
READ Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio that covers the company's technology and formulations related to pharmaceutical preparations that contain natural or synthetic cannabinoids.
Canntab is currently developing a number of products that use this technology, which includes a variety of extended released tablets containing a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that can be used to treat a number of ailments, such as sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, and the pain management and appetite loss associated with cancer treatments.
The company is currently awaiting a decision from Health Canada on its extended release tablets and is making batches of the tablets for third party clinical trials in Canada.